 Carbidopa
"Carbidopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.
| Descriptor ID |
D002230
|
| MeSH Number(s) |
D02.092.311.200.538.200 D02.442.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Carbidopa".
Below are MeSH descriptors whose meaning is more specific than "Carbidopa".
This graph shows the total number of publications written about "Carbidopa" by people in this website by year, and whether "Carbidopa" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Carbidopa" by people in Profiles.
-
Pettit NN, Alonso V, Wojcik E, Anyanwu EC, Ebara L, Benoit JL. Possible serotonin syndrome with carbidopa-levodopa and linezolid. J Clin Pharm Ther. 2016 Feb; 41(1):101-3.
-
Domschke K, Winter B, Gajewska A, Unterecker S, Warrings B, Dlugos A, Notzon S, Nienhaus K, Markulin F, Gieselmann A, Jacob C, Herrmann MJ, Arolt V, Mühlberger A, Reif A, Pauli P, Deckert J, Zwanzger P. Multilevel impact of the dopamine system on the emotion-potentiated startle reflex. Psychopharmacology (Berl). 2015 Jun; 232(11):1983-93.
-
Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, Hambuch T, Lu F, Lyon E, Voelkerding KV, Zehnbauer BA, Agarwala R, Bennett SF, Chen B, Chin EL, Compton JG, Das S, Farkas DH, Ferber MJ, Funke BH, Furtado MR, Ganova-Raeva LM, Geigenmüller U, Gunselman SJ, Hegde MR, Johnson PL, Kasarskis A, Kulkarni S, Lenk T, Liu CS, Manion M, Manolio TA, Mardis ER, Merker JD, Rajeevan MS, Reese MG, Rehm HL, Simen BB, Yeakley JM, Zook JM, Lubin IM. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol. 2012 Nov; 30(11):1033-6.
-
Mitala CM, Wang Y, Borland LM, Jung M, Shand S, Watkins S, Weber SG, Michael AC. Impact of microdialysis probes on vasculature and dopamine in the rat striatum: a combined fluorescence and voltammetric study. J Neurosci Methods. 2008 Sep 30; 174(2):177-85.
-
Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, Turk MF, Burnett OL. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord. 1999 Nov; 14(6):940-6.
-
Dewey RB, Maraganore DM, Ahlskog JE, Matsumoto JY. Intranasal apomorphine rescue therapy for parkinsonian "off" periods. Clin Neuropharmacol. 1996 Jun; 19(3):193-201.
-
Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, O'Brien PC. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology. 1993 Oct; 43(10):1918-26.
-
Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE, Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology. 1993 Oct; 43(10):1981-4.
-
Klawans HL, Paleologos N. Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists. Clin Neuropharmacol. 1986; 9(3):298-302.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|